

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(Use as many sheets as necessary)

Application Number	10/023,584
Filing Date	December 21, 2001
First Named Inventor	Rosen, Craig A.
Art Unit	1647
Examiner Name	Landsman, Robert S.
Attorney Docket Number	1488.100000Q/HCC/LMB

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² Number ³ Kind Code ³ (if known)				
BL	FP24	EP 0 186 084 A2	07/02/1986	Merck & Co. Inc.		
	FP25	JP 64-38100 A	02/08/1989	Toray Ind. Inc.		
	FP26	JP 2-117698 A	05/02/1990	Ajinomoto KK and Toray Ind. Inc.		
	FP27	EP 0 399 816 A1	11/28/1990	Merck & Co. Inc.		
	FP28	WO 94/11506 A1	05/26/1994	Arch Development Corporation		
	FP29	WO 00/45835 A1	08/10/2000	Human Genome Sciences, Inc. and Rosen <i>et al.</i>		
	FP30	WO 02/11769 A1	02/14/2002	Human Genome Sciences, Inc. and Coleman		
V	FP31	WO 02/083704 A1	10/24/2002	Human Genome Sciences, Inc. and Rosen <i>et al.</i>		

4.7.06

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Application Number	10/023,584
Filing Date	December 21, 2001
First Named Inventor	Rosen, Craig A.
Art Unit	1647
Examiner Name	Landsman, Robert S.
Attorney Docket Number	1488.100000Q/HCC/LMB


Sheet	2	of	2
-------	---	----	---

[illegible][illegible]

Examiner Signature	<i>Deise</i>	Date Considered	4.7.06
-----------------------	--------------	--------------------	--------

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (07-05)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/023,584
				Filing Date	December 21, 2001
				First Named Inventor	Rosen, Craig A.
				Art Unit	1647
				Examiner Name	Landsman, Robert S.
Sheet	1	of	4	Attorney Docket Number	1488.100000Q/HCC/LMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
PL	NPL23	Borg, J.-P., <i>et al.</i> , "Biochemical characterization of two isoforms of FLT4, a VEGF receptor-related tyrosine kinase," <i>Oncogene</i> 10:973-984, Stockton Press (March 1995)	
	NPL24	Capogrossi, M.C., "Gene Therapy of Coronary Artery Disease," Project No. Z01 AG00811-01, Abstract (January 1994)	
	NPL25	Capogrossi, M.C., "Gene Therapy of Coronary Artery Disease," Project No. Z01 AG00811-02, Abstract (January 1995)	
	NPL26	Choi, I.H., <i>et al.</i> , "Angiogenesis and Mineralization During Distraction Osteogenesis," <i>J. Korean Med. Sci.</i> 17:435-447, The Korean Academy of Medical Sciences (August 2002)	
	NPL27	Copy of Declaration of Dr. Kari Alitalo, In re of: U.S. Application No. 08/585,895, Alitalo <i>et al.</i> , filed January 12, 1996, submitted November 26, 1997	
	NPL28	Dias, S., <i>et al.</i> , "Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy," <i>Blood</i> 99:2179-2184, The American Society of Hematology (March 2002)	
	NPL29	English language abstract of JP 64-38100 A, cited as document FP25 on Form PTO/SB/08A, Derwent Accession No. 1989-088700/198912	
	NPL30	English language abstract of JP 2-117698 A, cited as document FP26 on Form PTO/SB/08A, Derwent Accession No. 1990-181364/199024	
	NPL31	Fan, T.-P.D., <i>et al.</i> , "Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy," <i>Trends Pharmacol. Sci.</i> 16:57-66, Elsevier Science Ltd. (February 1995)	
✓	NPL32	Isner, J.M., <i>et al.</i> , "Arterial Gene Therapy for Therapeutic Angiogenesis in Patients With Peripheral Artery Disease," <i>Circulation</i> 91:2687-2692, American Heart Association, Inc. (June 1995)	

Examiner Signature		Date Considered	4.7.06
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/023,584
				Filing Date	December 21, 2001
				First Named Inventor	Rosen, Craig A.
				Art Unit	1647
				Examiner Name	Landsman, Robert S.
Sheet	2	of	4	Attorney Docket Number	1488.100000Q/HCC/LMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
PL	NPL33	Isner, J.M. and Feldman, L.J., "Gene therapy for arterial disease," <i>Lancet</i> 344:1653-1654, The Lancet Ltd. (December 1994)	
	NPL34	Isner, J.M., <i>et al.</i> , "Physiologic Assessment of Angiogenesis by Arterial Gene Therapy with Vascular Endothelial Growth Factor," <i>J. Cell. Biochem. (Suppl. 21A)</i> :378, Abstract C6-215, Wiley-Liss (March-April 1995)	
	NPL35	Isner, J.M., "Therapeutic Angiogenesis in Vascular Medicine," Project No. R01 HL53354-01, Abstract (March 1995)	
	NPL36	Kubo, H., <i>et al.</i> , "Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea," <i>Proc. Natl. Acad. Sci.</i> 99:8868-8873, The National Academy of Sciences (June 2002)	
	NPL37	Kuzuya, M. and Kinsella, J.L., "Induction of Endothelial Cell Differentiation <i>in Vitro</i> by Fibroblast-Derived Soluble Factors," <i>Exp. Cell Res.</i> 215:310-318, Academic Press, Inc. (December 1994)	
	NPL38	Maher, P.A., "Stimulation of Endothelial Cell Proliferation by Vanadate Is Specific for Microvascular Endothelial Cells," <i>J. Cell. Physiol.</i> 151:549-554, Wiley-Liss, Inc. (1992)	
	NPL39	Mesri, E.A., <i>et al.</i> , "Expression of Vascular Endothelial Growth Factor From a Defective Herpes Simplex Virus Type 1 Amplicon Vector Induces Angiogenesis in Mice," <i>Circulation Res.</i> 76:161-167, American Heart Association, Inc. (February 1995)	
	NPL40	Mühlhauser, J., <i>et al.</i> , "In Vivo Gene Transfer into Porcine Cardiac Cells with a Replication-Deficient Recombinant Adenovirus Vector," <i>Circulation</i> 88:I-475, Abstract No. 2558, American Heart Association (October 1993)	
	NPL41	Mühlhauser, J., <i>et al.</i> , "VEGF ₁₆₅ Expressed by a Replication-Deficient Recombinant Adenovirus Vector Induces Angiogenesis <i>In Vivo</i> ," <i>Circulation Res.</i> 77:1077-1086, American Heart Association, Inc (December 1995)	
✓	NPL42	Oikawa, T., <i>et al.</i> , "Three Isoforms of Platelet-Derived Growth Factors All Have the Capability to Induce Angiogenesis <i>In Vivo</i> ," <i>Biol. Pharm. Bull.</i> 17:1686-1688, (December 1994)	

Examiner Signature		Date Considered	4.7.06
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
TENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/023,584
				Filing Date	December 21, 2001
				First Named Inventor	Rosen, Craig A.
				Art Unit	1647
				Examiner Name	Landsman, Robert S.
Sheet	3	of	4	Attorney Docket Number	1488.100000Q/HCC/LMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
BCL	NPL43	Pajusola, K., <i>et al.</i> , "Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors," <i>Oncogene</i> 9:3545-3555, Macmillan Press Ltd. (December 1994)	
	NPL44	Pepper, M.S., <i>et al.</i> , "In Vitro Angiogenic and Proteolytic Properties of Bovine Lymphatic Endothelial Cells," <i>Exp. Cell Res.</i> 210:298-305, Academic Press, Inc. (January 1994)	
	NPL45	Plate, K.H., "From angiogenesis to lymphangiogenesis," <i>Nat. Med.</i> 7:151-152, Nature America, Inc. (February 2001)	
	NPL46	Spranger, J. and Pfeiffer, A.F.H., "New concepts in pathogenesis and treatment of diabetic retinopathy," <i>Exp. Clin. Endocrinol. Diabetes</i> 109(Suppl. 2):S438-S450, J.A. Barth Verlag (2001)	
	NPL47	Symes, J.F. and Sniderman, A.D., "Angiogenesis: potential therapy for ischaemic disease," <i>Curr. Opin. Lipidol.</i> 5:305-312, Current Science Ltd. (August 1994)	
	NPL48	Takeshita, S., <i>et al.</i> , "In Vivo Evidence of Enhanced Angiogenesis Following Direct Arterial Gene Transfer of the Plasmid Encoding Vascular Endothelial Growth Factor," <i>Circulation</i> 88:I-476, Abstract No. 2565, American Heart Association (October 1993)	
	NPL49	Takeshita, S., <i>et al.</i> , "Therapeutic Angiogenesis. A Single Intraarterial Bolus of Vascular Endothelial Growth Factor Augments Revascularization in a Rabbit Ischemic Hind Limb Model," <i>J. Clin. Invest.</i> 93:662-670, The American Society for Clinical Investigation, Inc. (February 1994)	
	NPL50	Walsh, D.A. and Pearson, C.I., "Angiogenesis in the pathogenesis of inflammatory joint and lung diseases," <i>Arthritis Res.</i> 3:147-153, BioMed Central Ltd. (February 2001)	
	NPL51	Williams, R.S., "Southwestern Internal Medicine Conference: Prospects for Gene Therapy of Ischemic Heart Disease," <i>Am. J. Med. Sci.</i> 306:129-136, Lippincott Williams & Wilkins (August 1993)	
✓	NPL52	Witzenbichler, B., <i>et al.</i> , "Vascular Endothelial Growth Factor-C (VEGF-C/VEGF-2) Promotes Angiogenesis in the Setting of Tissue Ischemia," <i>Am. J. Pathol.</i> 153:381-394, American Society for Investigative Pathology, Inc. (August 1998)	

Examiner Signature	<i>Robert S. Landsman</i>	Date Considered	4.7.06
--------------------	---------------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible]

Examiner Signature	<i>Leidle</i>	Date Considered	4.7.06
-----------------------	---------------	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Equivalent of Form PTO/SB/08A (07-05)
Approved for use through 07/31/2006.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
ELEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/023,584
				Filing Date	December 21, 2001
				First Named Inventor	Rosen, Craig A.
				Art Unit	1647
				Examiner Name	Landsman, Robert S.
Sheet	1	of	1	Attorney Docket Number	1488.100000Q/HCC/LMB

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
AL	US12	2006/0014252 A1	01/19/2006	Lyman	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

505842_1.DOC

Examiner Signature		Date Considered	4.7.06
-----------------------	---	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
ELEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/023,584
				Filing Date	December 21, 2001
				First Named Inventor	Rosen, Craig A.
				Art Unit	1647
				Examiner Name	Landsman, Robert S.
Sheet	1	of	4	Attorney Docket Number	1488.100000Q/HCC/LMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
PL	NPL54	Danis, R.P., <i>et al.</i> , "Anti-angiogenic therapy of proliferative diabetic retinopathy," <i>Exp. Opin. Pharmacother.</i> 2:395-407, Ashley Publications Ltd. (March 2001)	
	NPL55	Enholtm, B., <i>et al.</i> , "Vascular Endothelial Growth Factor-C: A Growth Factor for Lymphatic and Blood Vascular Endothelial Cells," <i>Trends Cardiovasc. Med.</i> 8:292-297, Elsevier Science Inc. (October 1998)	
	NPL56	Ferrara, N., "Vascular Endothelial Growth Factor and the Regulation of Angiogenesis," <i>Recent Progress Hormone Res.</i> 55:15-36, The Endocrine Society (March 2000)	
	NPL57	Halin, C. and Neri, D., "Antibody-Based Targeting of Angiogenesis," <i>Crit. Rev. Ther. Drug Carrier Systems</i> 18:299-339, Begall House, Inc. (August 2001)	
	NPL58	Longo, R., <i>et al.</i> , "Anti-angiogenic therapy: Rationale, challenges, and clinical studies," <i>Angiogenesis</i> 5:237-256, Kluwer Academic Publishers (January 2002)	
	NPL59	Statutory Declaration of Kari Alitalo, executed on August 14, 2002, and accompanying Exhibits KA-1 and KA-2	
	NPL60	Statutory Declaration of Peter Adrian Walton Rogers, executed on August 9, 2002	
	NPL61	Statutory Declaration of Francis John Ballard, executed on July 16, 2002	
	NPL62	Statutory Declaration of Kari Alitalo, executed on July 16, 2002, and accompanying Exhibit 1	
V	NPL63	Statutory Declaration of Susan Power, executed on March 22, 2002, and accompanying Appendices I-IV	

Examiner Signature		Date Considered	4.7.06
-----------------------	---	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO ELEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/023,584
				Filing Date	December 21, 2001
				First Named Inventor	Rosen, Craig A.
				Art Unit	1647
				Examiner Name	Landsman, Robert S.
				Attorney Docket Number	1488.100000Q/HCC/LMB
Sheet	2	of	4		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
BL	NPL64	Statutory Declaration of Nicholas Kim Hayward, executed on March 26, 2002	
	NPL65	Statutory Declaration of Stuart A. Aaronson, executed on March 22, 2002, and accompanying Appendices I-III	
	NPL66	Statutory Declaration of Gary Baxter Cox, executed on March 22, 2002, and accompanying Exhibit GBC-24	
	NPL67	Statutory Declaration of Francis John Ballard, executed on December 12, 2001, and accompanying Exhibit FJB-1	
	NPL68	Statutory Declaration of Kari Alitalo, executed on September 24, 2001, and accompanying Exhibits 1-2	
	NPL69	Statutory Declaration of Peter Adrian Walton Rogers, executed on November 12, 2001, and accompanying Exhibits PAWR1-PAWR14	
	NPL70	Statutory Declaration of John Stanley Mattick, executed on December 12, 2000, and accompanying Exhibits JSM1-JSM4	
	NPL71	Statutory Declaration of Nicholas Kim Hayward, executed on December 8, 2000, and accompanying Exhibits NKH1-NKH2	
	NPL72	Statutory Declaration of Jennifer Ruth Gamble, executed on December 12, 2000, and accompanying Exhibits JRG1-JRG3	
✓	NPL73	Statutory Declaration of Tom Rapoport, executed on December 13, 2000, and accompanying Exhibits TP1-TP2	

Examiner Signature		Date Considered	4.7.06
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO ELEVENTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/023,584
				Filing Date	December 21, 2001
				First Named Inventor	Rosen, Craig A.
				Art Unit	1647
				Examiner Name	Landsman, Robert S.
				Attorney Docket Number	1488.100000Q/HCC/LMB
Sheet	3	of	4		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
BL	NPL74	Statutory Declaration of Stuart A. Aaronson, executed on December 14, 2000, and accompanying CV	
	NPL75	Statutory Declaration of Susan Power, executed on December 13, 2000, and accompanying Appendices 1-2 and Figure 1	
	NPL76	Statutory Declaration of Gary Baxter Cox, executed on December 13, 2000, and accompanying Exhibits GBC1-GBC23	
	NPL77	Statutory Declaration of Peter Adrian Walton Rogers, executed on February 16, 2000, and accompanying Exhibit 1	
	NPL78	Statutory Declaration of Francis John Ballard, executed on February 16, 2000, and accompanying Exhibit 1	
	NPL79	Statutory Declaration of Kari Alitalo, executed on February 15, 2000, and accompanying Exhibits 1-3	
	NPL80	Anderson, W.F., "Human gene therapy," <i>Nature</i> 392:25-30, Macmillan Magazines Ltd. (April 1998)	
	NPL81	Maynard, J. and Georgiou, G., "Antibody Engineering," <i>Annu. Rev. Biomed. Eng.</i> 2:339-376, Annual Reviews (August 2000)	
	NPL82	Morea, V., <i>et al.</i> , "Antibody Modeling: Implications for Engineering and Design," <i>Methods</i> 20:267-279, Academic Press (March 2000)	
V	NPL83	Stacker, S.A. and Achen, M.G., "The Vascular Endothelial Growth Factor Family: Signalling for Vascular Development," <i>Growth Factors</i> 17:1-11, Taylor & Francis (1999)	

Examiner Signature		Date Considered	4.7.06
--------------------	--	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

[illegible]


Examiner Signature	<i>Leche</i>	Date Considered	4.7.06
-----------------------	--------------	--------------------	--------

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible]

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ²
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			
BL	FP10	WO-98/06844	02-19-1998	Human Genome Sciences, Inc.	
	FP11	WO-98/24811	06-11-1998	Zymogenetics, Inc.	
	FP12	WO-98/39035	09-11-1998	The Wistar Institute of Anatomy & Biology	
	FP13	WO-98/49300	11-05-1998	Collateral Therapeutics	
	FP14	WO-98/55619	12-10-1998	ASAT AG Applied Science & Technology	
	FP15	WO-98/56936	12-17-1998	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	
	FP16	WO-99/02545	01-21-1999	Novopharm Biotech, Inc.	
	FP17	WO-99/08522	02-25-1999	Ludwig Institute for Cancer Research/Univ. Helsinki Licensing Ltd.	
V	FP18	WO-99/20749	04-29-1999	Medical Research Council	

Examiner Signature		Date Considered	4.7.06
-----------------------	---	--------------------	--------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 601.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

NINTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/023,584
				Filing Date	December 21, 2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Landsman, Robert S.
Sheet	1	of	3	Attorney Docket Number	1488.100000Q/EKS/HCC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
PL	NPL1	ALTSHULER <i>et al.</i> , "Taurine promotes the differentiation of a vertebrate retinal cell type in vitro," <i>Development</i> 119:1317-1328, The Company of Biologists Limited (December 1993)	
	NPL2	BOCKER-MEFFERT <i>et al.</i> , "Erythropoietin and VEGF Promote Neural Outgrowth from Retinal Explants in Postnatal Rats," <i>Invest. Ophthalmol. Vis. Sci.</i> 43:2021-2026, Association for Research in Vision and Ophthalmology (June 2002)	
	NPL3	GERHARDINGER <i>et al.</i> , "Expression of Vascular Endothelial Growth Factor in the Human Retina and in Nonproliferative Diabetic Retinopathy," <i>Am. J. Pathol.</i> 152:1453-1462, American Society for Investigative Pathology (June 1998)	
	NPL4	HANNINK <i>et al.</i> , "Deletions in the C-Terminal Coding Region of the v-sis Gene: Dimerization Is Required for Transformation" <i>Mol. And Cellular Biol.</i> 6:1304-1314, American Society for Microbiology (1986)	
	NPL5	HIRAI <i>et al.</i> , "Expression of Vascular Endothelial Growth Factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in Postmenopausal Uterine Endometrial Carcinoma," <i>Gynecol. Oncol.</i> 80:181-188, Academic Press (February 2001)	
	NPL6	KELLEY <i>et al.</i> , "Regulation of a Proliferation and Photoreceptor Differentiation in Fetal Human Retinal Cell Cultures," <i>Invest. Ophthalmol. Vis. Sci.</i> 36:1280-1289, Association for Research in Vision and Ophthalmology (June 1995)	
	NPL7	NGO <i>et al.</i> , "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," in: <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Kenneth Merz, Jr. and Scott LeGrand, eds., Birkhauser, Boston, MA, pp. 491-495 (January 1994)	
	NPL8	RUDIKOFF <i>et al.</i> , "Single amino acid substitution altering antigen-binding specificity," <i>Proc. Natl. Acad. Sci. USA</i> , 79:1979-1983, National Academy of Science (1982)	
	NPL9	SCHLAEPPPI <i>et al.</i> , "Characterization of a new potent, in vivo neutralizing monoclonal antibody to human vascular endothelial growth factor." <i>J. Cancer Res. Clin. Oncol.</i> 125:336-342, Springer-Verlag (June 1999)	
V	NPL10	SCHRATZBERGER <i>et al.</i> , "Reversal of experimental diabetic neuropathy by VEGF gene transfer," <i>J. Clin. Invest.</i> 107:1083-1092, American Society for Clinical Investigation (May 2001)	

Examiner Signature		Date Considered	4.7.06
--------------------	--	-----------------	--------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
NINTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/023,584
				Filing Date	December 21, 2001
				First Named Inventor	Craig A. Rosen
				Art Unit	1647
				Examiner Name	Landsman, Robert S.
Sheet	2	of	3	Attorney Docket Number	1488.100000Q/EKS/HCC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
PL	NPL11	SCHULZ-KEY <i>et al.</i> , "Ciliary Neurotrophic Factor as a Transient Negative Regulator of Rod Development in Rat Retina," <i>Invest. Ophthalmol. Vis. Sci.</i> 43:3099-3108, Association for Research in Vision and Ophthalmology (September 2002)	
	NPL12	STACKER <i>et al.</i> , "The Vascular Endothelial Growth Factor Family: Signalling for Vascular Development," <i>Growth Factors</i> 17:1-11, Harwood Academic Publishers (March 1999)	
	NPL13	VALE <i>et al.</i> , "Percutaneous Electromechanical Mapping Demonstrates Efficacy of pVGI.1 (VEGF2) in an Animal Model of Chronic Myocardial Ischemia," <i>Circulation</i> (Supplement), 100:I-22, Lippincott, Williams & Wilkins (November 1999)	
	NPL14	VALE <i>et al.</i> , "Randomized, Single-Blind, Placebo-Controlled Pilot Study of Catheter-Based Myocardial Gene Transfer for Therapeutic Angiogenesis Using Left Ventricular Electromechanical Mapping in Patients with Chronic Myocardial Ischemia," <i>Circulation</i> , 103:17:2138-2143, Lippincott, Williams & Wilkins (May 2001)	
	NPL15	VAN DER FLIER <i>et al.</i> , "Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis." <i>J. Neuroimmunol.</i> 160:170-177, Elsevier B.V. (March 2005)	
	NPL16	VERMA <i>et al.</i> , "Gene therapy -- promises, problems and prospects," <i>Nature</i> 389:239-242, Nature Publishing Company (September 1997)	
	NPL17	WINKLER <i>et al.</i> , "Changing the antigen binding specificity by single point mutations of an Anti-p24 (HIV-1) antibody." <i>J. Immunol.</i> 165:4505-4514, The American Association of Immunologists (October 2000)	
	NPL18	YANG <i>et al.</i> , "Flk-1, a Receptor for Vascular Endothelial Growth Factor (VEGF), Is Expressed by Retinal Progenitor Cells," <i>J. Neurosci.</i> 16:6089-6099, Society for Neuroscience (October 1996)	
	NPL19	GenBank Accession No. S08167, PAULSSON <i>et al.</i> , "Balbiani ring 3 protein - midge (<i>Chironomus tentans</i>)," (first available April 1993 and last updated July 2000)	
✓	NPL20	NCBI Entrez, GenBank Report, Accession NO. AF010302, MANDRIOTA, S.J. and PEPPER, M.S. (first available and last updated July 1997)	

Examiner Signature		Date Considered	4.7.06
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible]

Examiner Signature		Date Considered	4.7.06
-----------------------	---	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.